Clinical trial NCT03463135: A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients
Official title: A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult and Adolescent Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Food Allergy
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2018-03-13
Enrollment: 27
Sex: ALL
Minimum age (years): 12
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objective:

To assess tolerability and safety of SAR439794 \[peanut extract (PE) sublingual immunotherapy (SLIT) adjuvanted with Glucopyranosyl Lipid A (GLA)\] after repeated sublingual (SL) daily administration in peanut allergic adult and adolescent patients.

Secondary Objective:

To assess pharmacodynamics of SAR439794 after repeated SL daily administration in peanut allergic adult and adolescent patients.

Detailed description: The total study duration per participant is approximately from 15 to 18 weeks (core study) from screening until end-of-study visit, and 2 phone calls at Week 26 and Week 52 after the last Investigational Medicinal Product (IMP) dose.

Eligibility criteria: Inclusion criteria :

* Male or female patients, between 18 and 55 years of age, inclusive and adolescents between 12 and 17 years of age (after enrollment of 20 adult patients completed the 6 weeks dose escalation period and the safety and tolerability is deemed acceptable).
* Physician-diagnosed peanut allergy OR convincing history of objective clinical symptoms consistent with immediate hypersensitivity within 4 hours following known ingestion of peanuts or peanut-containing food AND by the following combined criteria:
* Peanut-specific IgE (P-sIgE) \>5 kUA/L and Arah2-specific IgE (Arah2-sIgE) \>2 kUA/L,
* Skin Prick Test (SPT) to peanut allergen ≥5 mm compared to saline control.
* High-sensitivity C reactive protein (hs-CRP), fibrinogen and neutrophil count within laboratory normal range unless the Investigator considers an abnormality to be clinically irrelevant.
* Ability to perform spirometry based on the American Thoracic Society guidelines.
* Patient must be trained on the proper use of an injectable epinephrine device and should be able to use it.

Exclusion criteria:

* Any history or presence of autoimmune, cardiovascular disease, chronic lung disease, malignancy, psychiatric illness, or gastrointestinal inflammatory conditions, including celiac disease, inflammatory bowel disease and eosinophilic gastrointestinal disorders.
* History of severe anaphylaxis, documented hypotension, neurological compromise (confusion, loss of consciousness), or incontinence known or suspected to be caused by ingestion of peanut or that required treatment with 2 or more administrations of epinephrine or hospitalization.
* Daily oral steroid use for \>1 month during the past year, burst oral steroid course in the past 6 months, or \>1 burst oral steroid course in the past year.
* Asthma requiring \>1 hospitalization in the past year or \>1 emergency department visit in the past 6 months.
* Severe or poorly controlled atopic dermatitis.
* Diagnosis of eosinophilic esophagitis.
* Diagnosis of other severe or complicating medical problems.
* Primary immune deficiency.
* If female, pregnancy (defined as positive β-HCG \[human chorionic gonadotropin\] blood test), breastfeeding.
* If female of childbearing potential, unable to use an effective method of contraception to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
* Use of beta blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or monoamine oxidase inhibitors.
* Any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
* Any patient who cannot be contacted in case of emergency.
* Any patient who is the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
* Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis B virus core antibodies (anti-HBc Ab), anti-hepatitis C virus antibodies (anti-HCV Ab), anti-human immunodeficiency Virus 1 and 2 antibodies (anti-HIV1 and anti- HIV2 Ab).
* Presence of sublingual epithelium and oral mucosa wound or infection (abcess, ulcer, candidiasis, gingivitis, etc.) or painful tooth decay.
* Participation in any food immunotherapy interventional study within the past 6 months.
* Patients who had received any monophosphoryl lipid (MPL)- or glucopyranosyl lipid A (GLA)-containing products within the last 6 months.
* Patients who experienced a Grade 3 or higher treatment emergent adverse event following administration of a MPL- or GLA-containing product.
* Use within the past 6 months of systemic immunomodulatory treatment and biologics with an immune target, including Xolair®.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Adverse events (AEs)
timeFrame: Up to Week 52
Secondary outcomes:
measure: Assessment of pharmacodynamic (PD) parameter: Peanut-specific serum Immunoglobulin G (IgG) levels
timeFrame: Baseline to Day 85
measure: Assessment of PD parameter: Peanut-specific serum IgG levels
timeFrame: Baseline to Day 57
measure: Assessment of PD parameter: Peanut-specific serum Immunoglobulin E (IgE) levels
timeFrame: Baseline to Day 57, Baseline to Day 85
measure: Assessment of PD parameter: Skin Prick Test
timeFrame: On Day 85
measure: Maximum SLIT PE dose
timeFrame: On Day 85
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Investigational Site Number 8400004
state: Arkansas
city: Mission Viejo
country: United States
facility: Investigational Site Number 8400019
state: California
city: San Diego
country: United States
facility: Investigational Site Number 8400008
state: California
city: San Jose
country: United States
facility: Investigational Site Number 8400020
state: California
city: Stanford
country: United States
facility: Investigational Site Number 8400006
state: California
city: Denver
country: United States
facility: Investigational Site Number 8400013
state: Colorado
city: Louisville
country: United States
facility: Investigational Site Number 8400014
state: Kentucky
city: Baltimore
country: United States
facility: Investigational Site Number 8400002
state: Maryland
city: Boston
country: United States
facility: Investigational Site Number 8400001
state: Massachusetts
city: Minneapolis
country: United States
facility: Investigational Site Number 8400009
state: Minnesota
city: Minneapolis
country: United States
facility: Investigational Site Number 8400016
state: Minnesota
city: Charleston
country: United States
facility: Investigational Site Number 8400010
state: North Carolina
city: Cincinnati
country: United States
facility: Investigational Site Number 8400011
state: Ohio
city: Medford
country: United States
facility: Investigational Site Number 8400012
state: Oregon
city: Seattle
country: United States
facility: Investigational Site Number 8400003
state: Washington
city: Madison
country: United States
facility: Investigational Site Number 8400017
state: Wisconsin
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: